Disorders of Taste and Smell
- Author: Donald Leopold, MD; Chief Editor: Arlen D Meyers, MD, MBA more...
Introduction and Background
Historically, disorders of taste and smell have been difficult to diagnose and treat, often because of a lack of knowledge and understanding of these senses and their disease states. An alteration in taste or smell may be a secondary process in various disease states, or it may be the primary symptom.
The true prevalence of disorders of taste and smell in the general population is unknown. The best data available are from a 1994 survey, which revealed that 2.7 million American adults report an olfactory problem and 1.1 million adults report a gustatory problem. It is known that individuals tend to underreport olfactory impairment, indicating these values underestimate the true magnitude of these disorders.
It is also known that chemosensory dysfunction deteriorates with age; given the aging of the US population, it stands that a significant and increasing number of individuals will experience age-related sensory loss. A 2002 study showed the prevalence of objective olfactory impairment in adults older than 53 years is 24.5% and grows more prevalent with age, to 62.5 % in those aged 80-97 years. Extrapolating from these values, there are currently 14 million older adults with some degree of olfactory impairment. Self-reported impairment in this study was only 9.5%, which supports the need for more accurate data based on objective measures.
Fortunately, the National Health and Nutrition Examination Survey (NHANES) adopted smell and taste testing in January 2013, with plans to release updated data in 2015 regarding the prevalence and impact of loss of taste and smell across the entire US population.
Loss of smell and/or taste has been linked to inadequate nutritional intake, reduced social pleasure, and decreased psychological wellbeing. It may even be life threatening, impairing the detection of smoke in a fire or the ability to identify spoiled food. Because approximately 80% of taste disorders are truly smell disorders, much of this article focuses on the sense of smell and its dysfunction, with additional discussion of taste and related disorders. See the image below.
The disorders of smell are classified as "-osmias" and those of taste as "-geusias."
Anosmia - Inability to detect odors
Hyposmia - Decreased ability to detect odors
Dysosmia - Distorted identification of smell
- Parosmia - Altered perception of smell in the presence of an odor, usually unpleasant
- Phantosmia – Perception of smell without an odor present
- Agnosia - Inability to classify or contrast odors, although able to detect odors
Ageusia - Inability to taste
Hypogeusia - Decreased ability to taste
Dysgeusia – Distorted ability to taste
Smell and taste disorders can be total (all odors or tastes), partial (affecting several odors or tastes), or specific (only one or a select few odors or tastes).
Anatomy and Physiology
The olfactory neuroepithelium is located at the upper area of each nasal chamber adjacent to the cribriform plate, superior nasal septum, and superior-lateral nasal wall. It is a specialized pseudostratified neuroepithelium containing the primary olfactory receptors. In neonates, this area is a dense neural sheet, but, in children and adults, the respiratory and olfactory tissues interdigitate. As humans age, the number of olfactory neurons steadily decreases. In addition to the olfactory neurons, the epithelium is composed of supporting cells, Bowman glands and ducts unique to the olfactory epithelium, and basal cells that allow for the regeneration of the epithelium.
The sense of smell is mediated through stimulation of the olfactory receptor cells by volatile chemicals. To stimulate the olfactory receptors, airborne molecules must pass through the nasal cavity with relatively turbulent air currents and contact the receptors. Odorants can also be perceived by entering the nose posteriorly through the nasopharynx to reach the olfactory receptor via retronasal olfaction. This mechanism is thought to play a key role in the sensation of flavor during eating and drinking. Odorants diffuse into the mucous and are transported to the olfactory receptor with the help of odorant-binding proteins. Important determinants of an odor's stimulating effectiveness include duration, volume, and velocity of a sniff.
Each olfactory receptor cell is a primary sensory bipolar neuron. The average nasal cavity contains more than 100 million such neurons. The olfactory neurons are unique because they are generated throughout life by the underlying basal cells. New receptor cells are generated approximately every 30-60 days.
Each regenerating receptor cell extends its axon (CN I) into the CNS as a first-order olfactory neuron and forms synapses with target mitral and tufted cells in the olfactory bulb.
The bipolar olfactory neurons have a short peripheral process and a long central process. The peripheral process extends to the mucosal surface to end in an olfactory knob, which has several immobile cilia forming a dense mat at the mucosal surface. The cilia express the olfactory receptors that interact with odorants. The family of odor receptor proteins are G-protein coupled receptors (GPCRs) associated with adenylate cyclase. The genes that encode them were discovered in 1991 by Linda Buck and Richard Axel, culminating in the Nobel Prize awarded in 2004.
This family encompasses approximately 900 genes, the largest in the genome. It has been found in mice that each neuron expresses only one gene, so odorants are recognized by the complex binding pattern they create. This is most likely the case in humans as well. Interestingly, these genes have been recently discovered to exist in nonolfactory tissues such as sperm and the gut. The function of these genes outside of their role in olfaction is under investigation.
Once an odorant binds to its receptor, a signaling cascade depolarizes the neuron, which sends the signal along its axon, which then converges together within the bundled axons of the fila olfactoria deep to the epithelium.
These axons project through the cribriform plate to the ipsilateral olfactory bulb. The olfactory bulb cells contacted by the olfactory receptor cells include the mitral and tufted cells, arranged in specialized areas termed glomeruli. The axon terminals of receptorlike neurons synapse within the same glomeruli, forming an early topographical odorant map. Therefore, an odor is thought to activate a set of odorant receptors based on its chemical composition. The corresponding glomeruli of the olfactory bulbs are in turn activated, creating a unique pattern of excitation in the olfactory bulb for each odorant.
The glomerular cells are the primary output neurons of the olfactory bulb. Axons from these cells travel to the olfactory cortex, which is divided into 5 parts, including (1) the anterior olfactory nucleus, connecting the 2 olfactory bulbs through the anterior commissure, (2) the olfactory tubercle, (3) the pyriform cortex, which is the main olfactory discrimination region, (4) the cortical nucleus of the amygdala, and (5) the entorhinal area, which projects to the hippocampus.
The olfactory pathway does not involve a thalamic relay prior to its cortical projections. Relays from the olfactory tubercle and the pyriform cortex project to other olfactory cortical regions and to the medial dorsal nucleus of the thalamus and probably involve the conscious perception of odors.
Conversely, the cortical nucleus of the amygdala and the entorhinal area are limbic system components and may be involved in the affective, or hedonic, components of odors. Regional cerebral blood flow (measured with positron emission tomography) is significantly increased in the amygdala with introduction of a highly aversive odorant, and it is associated with subjective ratings of perceived aversiveness.
The vomeronasal organ (VNO), or Jacobson organ, is a bilateral membranous structure located within pits of the anterior nasal septum, deep to the nasal respiratory mucosa and next to the septal perichondria. Its opening in the nasal vestibule is visible in 91-97% of adult humans, and it is 2 cm from the nostril at the junction of the septal cartilage with the bony septum. Unlike lower animals, axons projecting from the VNO have not been found in postnatal humans.
The VNO is believed by some to detect external chemical signals termed pheromones or vomeropherins through neuroendocrine-type cells found within the organ. These signals are not detected as perceptible smells by the olfactory system and may mediate human autonomic, psychologic, and endocrine responses.
Free trigeminal nerve endings, which are stimulated by aversive or pungent stimuli (eg, ammonia), exist in the nasal mucosa. These are processed via separate pathways from those in the olfactory system, described above.
Taste perception is mediated by individual taste buds, with 50-100 tightly packed cells in each bud. Taste buds are modified epithelial cells, not direct neurons as in olfactory function. Taste bud cells are classified into types I-IV and include taste receptor, supporting and basal progenitor cells. These cells have a life span of approximately 10 days and arise continuously from the underlying basal cell layer in a process of constant turnover, similar to olfactory receptor cells. Any bud may contain receptors necessary to identify each different taste.
Afferent nerve branches making synaptic contact with receptor cells penetrate the base of the taste bud. Taste buds occupy papillae, which are projections embedded in the tongue epithelium. A single nerve fiber innervates multiple taste papillae, and the nerve contact exerts trophic influences on the epithelium.
The specificity of the gustatory receptor cells is determined by the epithelium in which it resides, not by the particular nerve innervating the bud. A single fiber in the chorda tympani may respond to multiple types of tastes, some tastes more than others. This ability of single nerve fibers to respond to multiple types of stimuli is referred to as broad tuning, and it is shared by the olfactory system.
Lingual papillae have the following 4 forms, each occupying different areas of the tongue:
Fungiform papillae are located in the anterior two thirds of the tongue. People have an average of 33 fungiform papillae with approximately 114 buds per papilla. Innervation is through cranial nerve (CN) VII via the chorda tympani.
Circumvallate papillae are located in the posterior two thirds of the tongue, consisting of 8-12 papillae, approximately 250 buds each, for an average of 3000 total buds. Cranial nerve IX innervates these, along with the entire posterior one third of the tongue.
Foliate papillae reside in folds and clefts at the lateral borders of the tongue, with approximately 1280 buds. Cranial nerve IX innervates these buds.
Filiform papillae have no taste buds.
Other locations of taste buds include the following:
Soft palate - Innervated by CN VII via the greater superficial petrosal nerve
Epiglottis and larynx - Supplied by the superior laryngeal branch of CN X
Pharynx - Supplied by branches from CN IX and CN X
Free trigeminal nerve endings exist on the tongue; these detect strong, often displeasing or irritating sensations in the oral cavity.
Five different taste qualities—salty, sweet, sour, bitter, and umami (monosodium glutamate/5' nucleotide)—have been identified. In addition, there is evidence that another taste perception exists, the ability to sense lipid content. Similar to odorant transmission, most tastes are mediated by various GPCRs. Sweet, umami, and bitter are detected by members of 2 GPCR families, taste 1 receptor family (TAS1R) and taste 2 receptor family (TAS2R). Lipid content is mediated by a free fatty acid receptor. In contrast, sour and salty are mainly mediated by ion channels.
Ongoing research has identified odor and taste receptors in surprising places, including skeletal muscle, brain, respiratory tract, and GI tract. Evidence shows taste receptors present from the stomach to the colon function in nutrient sensing. The exact role of these receptors in regions other than the nose and mouth needs to be further elucidated. Doing so offers promise in terms of our understanding of human physiology and targets for novel therapeutic interventions.
Etiology of Smell and Taste Disorders
Disturbances in olfaction can result from pathologic processes at any level along the olfactory pathway. They can be classified in a way analogous to otologic dysfunction, as conductive or sensorineural defects. In conductive (ie, transport) defects, transmission of an odorant stimulus to the olfactory neuroepithelium is disrupted. Sensorineural defects involve the more central neural structures. Overall, the most common causes of primary olfactory deficits are aging, nasal and/or sinus disease, prior viral upper respiratory tract infections (URTIs), and head trauma.
Inflammatory processes cause a large portion of olfactory defects. These may include rhinitis of various types, including allergic, acute, or toxic (eg, cocaine use). Chronic rhinosinusitis causes progressive mucosal disease and often leads to decreased olfactory function despite aggressive allergic, medical, and surgical intervention.
Masses may block the nasal cavity, preventing the flow of odorants to the olfactory epithelium. These include nasal polyps (most common), inverting papilloma, or any nasal tumor.
Developmental abnormalities (eg, encephaloceles, dermoid cysts) also may cause obstruction.
Patients with laryngectomies or tracheotomies experience hyposmia because of a reduced or absent nasal airflow. Children with tracheotomies who are cannulated very young and for a long period may have a continued problem with olfaction even after decannulation because of a lack of early stimulation of the olfactory system.
Infectious and inflammatory processes contribute to central defects in olfaction and in transmission. These include viral infections (which may damage the neuroepithelium), sarcoidosis (affecting neural structures), Wegener granulomatosis, and multiple sclerosis. Once thought to be mostly a conductive defect through mucosal edema and polyp formation, chronic rhinosinusitis also appears to disrupt the neuroepithelium with irreversible loss of olfactory receptors through up-regulated apoptosis.
Head trauma, brain surgery, or subarachnoid hemorrhage may stretch, damage, or transect the delicate fila olfactoria or damage brain parenchyma and result in anosmia.
Sense of smell decreases with age, and it has been shown that the number of fibers in the olfactory bulb decreases throughout one's lifetime. In one study the average loss in human mitral cells was 520 cells per year with a reduction in bulb volume of 0.19 mm3. These olfactory bulb losses may be secondary to sensory cell loss in the olfactory mucosa and/or general decline in the regenerative process from stem cells in the subventricular zone.
Congenital syndromes may be associated with neural losses. Kallmann syndrome is one type of congenital smell loss and is due to failed olfactory structure ontogenesis and hypogonadotropic hypogonadism. One study found the vomeronasal organ to be absent in patients with Kallmann syndrome.
Endocrine disturbances (eg, hypothyroidism, hypoadrenalism, diabetes mellitus) may affect olfactory function.
Toxicity of systemic or inhaled drugs (eg, aminoglycosides, formaldehyde) can contribute to olfactory dysfunction. Many other medications and compounds may alter smell sensitivity, including alcohol, nicotine, organic solvents, and direct application of zinc salts.
Over-the-counter zinc nasal sprays have been implicated in the cause of smell loss. On June 16, 2009, the US Food and Drug Administration (FDA) issued a public health advisory and notified consumers and healthcare providers to discontinue use of intranasal zinc products. The intranasal zinc products (Zicam Nasal Gel/Nasal Swab products by Matrixx Initiatives) are herbal cold remedies that claim to reduce the duration and severity of cold symptoms and are sold without a prescription. The FDA received more than 130 reports of anosmia (inability to detect odors) associated with intranasal zinc. Many of the reports described the loss of smell with the first dose.
Smoking has not been shown conclusively to reduce olfactory function, although some studies have shown a correlation with reduced sense of smell and smoking. That withstanding, research has identified squamous metaplasia and change in the morphology of the olfactory receptor neurons and a higher level of apoptosis of these neurons in smokers compared with controls. In addition, there is evidence that the volume of the olfactory bulb is reduced in smokers.
Various neuropsychiatric disorders (eg depression, schizophrenia, seasonal affective disorder) have been linked to hyposmia. It has been shown that patients with acute major depressive disorder have reduced olfactory sensitivity and reduced olfactory bulb volumes. Schizophrenia patients have also been shown to have decreased olfactory bulb volume and impaired odor detection abilities compared with controls. The neurologic explanation for these findings is under active investigation and may lead to new therapies or early detection screening tools.
Degenerative processes of the central nervous system (eg, Parkinson disease, Alzheimer disease) and other neurologic diseases (Huntington disease, multiple sclerosis, motor neuron disease) have been associated with hyposmia. Alzheimer and Parkinson patients show changes in detection, discrimination, and identification of odors compared with age-matched controls. The severity of dysfunction is correlated to disease progression. In most cases, olfactory loss is present years before motor or cognitive symptoms. However, this is usually a gradual loss and often goes unnoticed or unreported by patients.
A study by Cecchini et al found severe olfactory impairment in persons with Down syndrome, with these individuals performing worse than euploid controls on tests of odor detection threshold, odor discrimination, and odor identification. Among 56 subjects with Down syndrome, 27 demonstrated functional anosmia.
The assessment of olfactory function should become a more standard aspect of patient evaluation. There are numerous functional and structural approaches available to assess the olfactory system, including psychosocial and electrophysiological testing, as well as imaging studies. Objective measures of olfactory function may serve as an early marker for these diseases or as a prognostic indicator. An understanding of the mechanism of the decrease in smell could help to further elucidate the pathophysiology of these disorders or uncover new treatments.[17, 18]
Much of what is perceived as a taste defect is truly a primary defect in olfaction resulting in an alteration of flavor. The components that comprise the sensation of flavor include the food's smell, taste, texture, and temperature. Each of these sensory modalities is stimulated independently to produce a distinct flavor when food enters the mouth.
Taste may be enhanced by tongue movements, which increase the distribution of the substance over a greater number of taste buds. Adaptation in taste perception exerts a greater influence than in other sensory modalities.
Other than smell dysfunction, the most frequent causes of taste dysfunction are prior URTI, head injury, and idiopathic causes, but many other causes can be responsible.
Lesions at any site from the mucosa, taste buds, unmyelinated nerves, or cranial nerves to the brain stem may impair gustation.
Oral cavity and mucosal disorders including oral infections, inflammation, and radiation-induced mucositis can impair taste sensation. The site of injury with radiotherapy is probably the microvilli of the taste buds, not the taste buds themselves, since taste buds are thought to be radioresistant.
Poor oral hygiene is a leading cause of hypogeusia and cacogeusia. Viral, bacterial, fungal, and parasitic infections may lead to taste disturbances because of secondary taste bud involvement.
Normal aging produces taste loss due to changes in taste cell membranes involving altered function of ion channels and receptors rather than taste bud loss.[2, 19]
Malignancies of the head and neck, as well as of other sites, are associated with decreased appetite and inability to appreciate flavors.
Use of dentures or other palatal prostheses may impair sour and bitter perception, and tongue brushing has been shown to decrease taste acuity.
Surgical manipulation may alter taste permanently or temporarily. Resection of the tongue and/or portions of the oral cavity, most commonly for reasons of malignancy, decreases the number of taste buds. Radiation and chemotherapy damage taste receptors and decrease salivary flow, altering taste perception. In otologic surgery, stretching or transection of the chorda tympani nerve may result in temporary dysgeusia. Bilateral injury still may not result in permanent taste dysfunction, because of the alternate innervation through the otic ganglion to the geniculate ganglion via the greater superficial petrosal nerve.
Gastric bypass surgery can also have adverse olfactory and gustatory effects. In a study by Graham et al of 103 patients who underwent Roux-en-Y gastric bypass, sensory changes in taste and smell were reported by 73% and 42% of these individuals, respectively.
Nutritional deficiencies are involved in taste aberrations. Decreased zinc, copper, and nickel levels can correlate with taste alterations. Nutritional deficiencies may be caused by anorexia, malabsorption, and/or increased urinary losses.
Endocrine disorders also are involved in taste and olfactory disorders. Diabetes mellitus, hypogonadism, Sjogren’s and pseudohypoparathyroidism may decrease taste sensation, while hypothyroidism and adrenal cortical insufficiency may increase taste sensitivity. Hormonal fluctuations in menstruation and pregnancy also influence taste.
AIDS patients often complain of alterations in taste, and detection thresholds of glutamic acid and hydrochloride are higher in patients suffering from AIDS.
Heredity is involved in some aspects of gustation. The ability to taste phenylthiourea (bitter) and other compounds with an –N-C= group is an autosomal dominant trait. Studies have shown that phenylthiourea tasters detect saccharin, potassium chloride (KCl), and caffeine as more bitter. Type I familial dysautonomia (ie, Riley-Day syndrome) causes severe hypogeusia or ageusia because of the absence of taste bud development.
Direct nerve or CNS damage, as in multiple sclerosis, facial paralysis, and thalamic or uncal lesions, can decrease taste perception.
Many other diseases can affect gustation (eg, lichen planus, aglycogeusia, Sjögren syndrome, renal failure with uremia and dialysis, erythema multiforme, geographic tongue, cirrhosis).
Diagnosis of Smell and Taste Disorders
The first step in diagnosing any deficit of taste and smell is obtaining a thorough history and physical examination. Give attention to any antecedent URI, nasal or sinus pathology, history of trauma, other medical problems, and medications taken.
Order sinus CT scans if the history and examination are not consistent with a common pattern (eg gradually progressing olfactory loss in a 38-year-old male). Generally, olfactory loss in the absence of CNS symptoms or an abnormal neurologic examination is highly unlikely to be associated with an intracranial mass such as a meningioma. However, an MRI of the brain is often recommended when the history is not straightforward or a secondary neurologic symptom or sign is obtained (eg, 50-year-old woman with a taste phantom that does not resolve after 6 months). Although a standard laboratory panel is not recommended, tests to evaluate for allergy, diabetes mellitus, thyroid functions, renal and liver function, endocrine function, and nutritional deficiencies may be obtained based on history and the physical examination. Olfactory epithelium biopsy is used primarily as a research technique.
Clinical measurement of olfaction
Quantitative measurement of smell and taste dysfunctions is most important when chemosensory dysfunction is the primary symptom. The major goal of sensory testing is to assess the degree of chemosensory dysfunction.
Clinical testing can be time consuming and difficult to perform precisely, but some commercially available tests attempt to simplify and standardize these efforts.
Tests of olfactory function that evaluate threshold of odor detection and odor identification have been developed that can provide a reliable measure of olfactory ability. These tests include butanol threshold test, the University of Pennsylvania Smell Identification Test (UPSIT) (Sensonics, Inc. www.sensonics.com), and the Sniffin' Sticks test (Burghart Messtechnik GmbH www.burghart-mt.de). Another test, the olfactory-evoked response, has been used in research centers along with odor identification tests to evaluate aberrant olfaction with relation to neurologic disease.
Butanol threshold test
The butanol threshold test involves a forced-choice test using an aqueous concentration of butyl alcohol in one sniff bottle and water in the other. The patient is asked to identify the bottle containing the odorant, with each nostril tested separately.
After each incorrect response, the concentration of butanol is increased by a factor of 3 until the patient either achieves 5 correct responses or fails to correctly identify the bottle with 4% butanol.
The detection threshold is recorded as the concentration at which the patient correctly identifies the butanol on 5 consecutive trials. The scoring relates the patient's threshold to a normal subject population
University of Pennsylvania Smell Identification Test
The UPSIT involves 40 microencapsulated odors in a scratch-and-sniff format, with 4 response alternatives accompanying each odor. The patient takes the test alone, with instructions to guess if not able to identify the item.
Anosmic patients tend to score at or near chance (10/40 correct). The scores are compared against sex- and age-related norms, and the results are analyzed. This test has excellent test-retest reliability.
A chart is available relating scores to varying patient populations, including patients with multiple sclerosis, with Korsakoff syndrome, and those feigning anosmia. Those in the latter group tend to score much lower on the test than expected by chance.
Cross-Cultural Smell Identification Test
A variant of the UPSIT, which can be given in 5 minutes, was proposed for a quick measure of olfactory function. The 12-item Cross-Cultural Smell Identification Test (CC-SIT) was developed using input on the familiarity of odors in several countries, including China, Colombia, France, Germany, Italy, Japan, Russia, and Sweden.
The odorants chosen include banana, chocolate, cinnamon, gasoline, lemon, onion, paint thinner, pineapple, rose, soap, smoke, and turpentine. Representatives from each country identified these odorants most consistently.
This test is an excellent alternative for measuring olfactory function in the clinical setting, especially when time is limited, since it is rapid and reliable.
The disadvantage of this test is that its brevity limits its sensitivity in detecting subtle changes in olfactory function.
These use a series of reusable penlike odor-dispensing devices and tests odor the threshold through a single staircase method, odor discrimination with forced choice among 3 of 16 different common odorants, and odor identification with multiple forced choice from 4 verbal items. A composite score is calculated from a composite of all 3 scores to provide an overall evaluation of olfactory function.
Olfactory-evoked response (usually reserved for research studies)
To standardize the patient reaction to eye movements, electroencephalogram (EEG) electrodes and an electrooculogram measure olfactory-evoked potentials. A visual tracking task is performed to ensure constant alertness to the task, and headphones playing white noise are worn to mask auditory clues.
Either carbon dioxide (no odor but a trigeminal stimulant) or hydrogen sulfide is delivered via an olfactometer to the nose in a constantly flowing air stream. N1 is the first negative peak measured, and P2 is the second positive trough. Latencies are measured to these 2 values.
In patients with neurologic disease, the UPSIT revealed abnormality more frequently than olfactory-evoked responses.
For clinical olfactory function testing, the authors' experience is that the self-administered UPSIT test allows for practical use during a busy clinical practice. However, in the absence of the olfactory tests described above, a simple screening test using a common alcohol pad can be used. The envelope is opened at one end and presented to the patient. With the patient's eyes closed, the pad is then positioned at the level of the umbilicus and slowly brought closer to the nose. The patient is instructed to notify the tester when the alcohol is again detected. The distance of the pad from the nose correlates with the patient's olfactory ability, with a distance of less than 20 cm indicating hyposmia.
Clinical measurement of taste
Evaluation of taste disorders is not as well developed as that of olfaction. It involves measurement of detection or recognition thresholds. No comparable approach to odor identification tests is available because only 5 basic taste sensations exist and only 4 of these (sweet, salty, bitter, and sour) are tested.
Salivary adaptation and size of the tongue area stimulated influence the threshold assessment. Thus, these tests are extremely variable. Changes in threshold detection do not necessarily indicate correlation to changes in suprathreshold taste intensity. Testing of the taste thresholds alone does not provide a full picture of the level of gustatory function or dysfunction. For example, a patient after radiation therapy may recover recognition thresholds for the 4 taste qualities, but the magnitude of the perceived tastes still may be quite depressed.
Taste Strips (Burghart, Messtechnik, Germany) are strips of paper that can be purchased and are already impregnated with 4 taste qualities: sweet, sour, salty, and bitter, each of these containing 4 different concentrations resulting in 16 strips in total. Specifically, these are sweet (0.4, 0.2, 0.1, 0.05 g/mL sucrose), sour (0.3, 0.165, 0.09, 0.05 g/mL citric acid), salty (0.25, 0.1, 0.04, 0.016 g/mL sodium chloride), and bitter (0.006, 0.0024, 0.0009, 0.0004 g/mL quinine hydrochloride). Normative values for these strips are available.
Suprathreshold testing involves assessment of the patient's perceptions of taste intensities at levels above threshold. One method of measuring this quality is with a psychophysical procedure known as magnitude matching.
Other tests of suprathreshold tastes have involved assigning numbers to their sensations, but no direct comparison across individuals can be made. Specific numbers, such as 10 or 100, do not have any intrinsic psychologic value.
Conversely, magnitude matching makes use of one sensory modality that is presumed to be normal (in this case, hearing) in comparison to a deficiency in another sensory modality (taste) by using the following procedure:
Several concentrations of sodium chloride, sucrose, citric acid, and quinine hydrochloric acid, along with several loudness levels of a 1000-Hz tone, are provided for the magnitude matching task. The patient sips each solution and expectorates, and the tones are presented via headphones. The patient provides estimates of perceived magnitude for each stimulus. The results are scaled in relation to loudness functions to reveal abnormalities of taste as depressed psychophysical functions. In other words, patients with hypogeusia associate stronger taste concentrations with weaker tones than normal patients. The major limitations of this testing modality are its dependence on normal hearing and its complicated design, which takes a significant amount of time to administer and analyze.
Taste function in the various areas of the tongue and oral cavity can be measured using a spatial test. Because the gustatory system is multiply innervated, damage to one of the 3 major nerves (ie, chorda tympani, glossopharyngeal, greater superficial petrosal) or their ganglia may cause a disturbance of taste that can be evaluated only by testing the anatomic areas supplied by those nerves.
To test these areas, 4 standardized sizes of filter paper are soaked with strong concentrations of the 4 basic tastes. The papers are randomly placed on the 4 quadrants of the tongue and on both sides of the soft palate. Patients then identify the quality of the taste and rate its intensity using the same scale as in whole mouth assessment.
Treatment of Olfactory and Gustatory Dysfunction
Treatment of olfactory dysfunction
Any treatment of olfactory disorders must first treat the specific causative abnormality if it has been identified from diagnostic tests, history, and physical examination.
Local nasal and/or sinus conditions should be optimally managed with saline lavage, decongestants, antihistamines, antibiotics, and/or nasal and systemic steroids, if applicable. Polyps and sinus disease that are resistant to medical management should be surgically addressed to remove the conductive defect. Care must be exercised during surgery to avoid damage to the olfactory regions.
Aggressive treatment of these disorders, if present, provides a good chance of improvement. In general, conductive olfactory losses are the most amenable to treatment.
A few of the sensorineural olfactory defects also have specific treatments, but these are fewer and have less chance of success. Generally, viral processes that damage the olfactory neuroepithelium, sarcoidosis, and multiple sclerosis do not have specific remedies; however, steroids may be administered in an attempt to limit the inflammation.
Endocrine disturbances may be addressed by administration of the deficient hormone, as with hypothyroidism. Control of diabetes mellitus may slow neural degeneration of the olfactory system. However, in a study of 12 males with Kallmann syndrome, Gong and Gao stated that, while the condition can be effectively treated with the administration of human chorionic gonadotropin (hCG), human menopausal gonadotropin (hMG), and testosterone undecanoate, there is currently no effective therapy for the olfactory dysfunction occurring in this disease.
Idiopathic cases of olfactory loss are not amenable to specific treatment, although some unproven remedies have been attempted. The best known of these is zinc sulfate. It has not been proven beneficial and is generally regarded as ineffective.
Other unproven remedies include pharmacologic doses of vitamins, topical steroids, and tricyclic antidepressants (for their effect on CSF catecholamines).
A viral URTI can cause extensive scarring and replacement of the olfactory neuroepithelium with respiratory epithelium, but studies suggest that stem cells remain, allowing for potential regeneration of the olfactory epithelium. Recovery of smell in these cases can take weeks to months and, in some instances, may never occur. It is now known that olfactory training is safe and effective therapy for postinfectious olfactory loss. This method involves the patient choosing 4 known odors and intentionally sniffing these same 4 odors twice daily. A recent randomized, controlled study showed improved olfactory function after 18 weeks, particularly in patients who started olfactory training within the first 12 months after onset. Eliminating toxins (eg, cigarette smoke, airborne pollutants) may help.
A literature review by Pekala et al indicated that olfactory training may be an effective treatment in patients with olfactory loss resulting from multiple etiologies, with improvements reported in discrimination between and identification of smells, although not in thresholds of odor detection.
Overall, the patient with olfactory disorders needs reassurance that these generally are not life-threatening problems and that many other individuals experience them. In some patients, psychiatric evaluation and treatment may be warranted. Most importantly, the physician is responsible for warning the patient with olfactory disorders of the hazards associated with the inability to smell odors such as smoke, natural gas leaks, and spoiled food. Smoke detectors, as well as natural gas and propane gas detectors, are commercially available to help eliminate such risks.
Treatment of gustatory dysfunction
As with olfactory problems, direct initial treatment of gustatory dysfunction toward the causative abnormality, if possible.
Address any nasal pathology causing decreased olfaction and thus affecting flavor perception.
Treat mucosal disorders (eg, infections, inflammations). Treat oral candidiasis and other local factors, and replete any vitamin deficiency that may cause glossitis.
Aid patients in eliminating local irritants (eg, mouthwashes, ill-fitting dentures)
In mucositis or dry mouth as a result of radiation therapy, artificial saliva or salivary stimulants and local anti-inflammatory medications may improve some taste dysfunction.
Correcting endocrine disorders with the appropriate hormone replacement may improve the taste disorder.
Consider eliminating a medication suspected of causing dysgeusia unless the medication is crucial in treating another medical problem and cannot be substituted.
In the case of familial dysautonomia, in which patients have a complete lack of lingual taste buds, subcutaneous administration of methacholine has been reported to normalize previously elevated taste thresholds for all taste qualities. The cholinergic mechanism is probably related to taste transduction via free nerve endings because these patients have no taste receptors.
Some gustatory deficits are untreatable (eg, some cases of nerve or CNS damage, end-stage diabetic neuropathy, multiple sclerosis).
Advise patients that chewing food well increases the release of the tastant and increases saliva production to further distribute the chemicals. Switching foods during the meal decreases the phenomenon of adaptation and can improve detection of the tastes.
Finally, for patients who are anosmic or hyposmic (including many elderly people), simulated odors are available to use while cooking to augment the sensation of flavor. A drawback of these simulated odors is that, to normosmic people, the smell is quite pungent. Thus, these odors cannot be used in mixed groups of anosmic and normosmic individuals.
Smell and taste disorders traditionally have been overlooked in most aspects of medical practice because these specialized senses often are not considered critical to life. However, they affect everyday enjoyment of food, and they impair detection of the potentially dangerous smells of smoke or spoiled food.
Anxiety and depression, as well as anorexia and nutritional deficiencies, may result from taste and smell disorders. Many causes of smell and taste disorders exist, and the modalities of treatment begin with treating the specific deficit, if possible.
Unfortunately, much about the diagnosis and treatment of taste and smell dysfunction remains to be discovered. Most "taste" defects are truly alterations in perception of flavor due to smell defects, and they should be treated accordingly.
Some standardized tests, such as the butanol threshold, odor identification, Sniffin' Sticks, UPSIT, and olfactory-evoked potentials, can help diagnose and measure olfactory dysfunction.
Reassurance is one of the most important aspects of treatment in these disorders because cures are often difficult to obtain and spontaneous resolution may take weeks, months, or years.
Hoffman HJ, Ishii EK, MacTurk RH. Age-related changes in the prevalence of smell/taste problems among the United States adult population. Results of the 1994 disability supplement to the National Health Interview Survey (NHIS). Ann N Y Acad Sci. 1998 Nov 30. 855:716-22. [Medline].
Boesveldt S, Lindau ST, McClintock MK, Hummel T, Lundstrom JN. Gustatory and olfactory dysfunction in older adults: a national probability study. Rhinology. 2011 Aug. 49(3):324-30. [Medline].
Murphy C, Schubert CR, Cruickshanks KJ, Klein BE, Klein R, Nondahl DM. Prevalence of olfactory impairment in older adults. JAMA. 2002 Nov 13. 288(18):2307-12. [Medline].
Patel RM, Pinto JM. Olfaction: Anatomy, physiology, and disease. Clin Anat. 2014 Jan. 27(1):54-60. [Medline].
Feng P, Huang L, Wang H. Taste bud homeostasis in health, disease, and aging. Chem Senses. 2014 Jan. 39(1):3-16. [Medline].
Foster SR, Roura E, Thomas WG. Extrasensory perception: Odorant and taste receptors beyond the nose and mouth. Pharmacol Ther. 2013 Nov 23. [Medline].
Depoortere I. Taste receptors of the gut: emerging roles in health and disease. Gut. 2014 Jan. 63(1):179-90. [Medline].
Allis TJ, Leopold DA. Smell and taste disorders. Facial Plast Surg Clin North Am. 2012 Feb. 20(1):93-111. [Medline].
Martin GE, Junque C, Juncadella M, Gabarros A, de Miquel MA, Rubio F. Olfactory dysfunction after subarachnoid hemorrhage caused by ruptured aneurysms of the anterior communicating artery. J Neurosurg. 2009 Apr 10. [Medline].
Bhatnagar KP, Kennedy RC, Baron G, Greenberg RA. Number of mitral cells and the bulb volume in the aging human olfactory bulb: a quantitative morphological study. Anat Rec. 1987 May. 218(1):73-87. [Medline].
Tuccori M, Lapi F, Testi A, Ruggiero E, Moretti U, Vannacci A, et al. Drug-induced taste and smell alterations: a case/non-case evaluation of an italian database of spontaneous adverse drug reaction reporting. Drug Saf. 2011 Oct 1. 34(10):849-59. [Medline].
United States Food and Drug Administration. Zicam cold remedy nasal products (Cold Remedy Nasal Gel, Cold Remedy Nasal Swabs, and Cold Remedy Saws, Kids Size). MedWatch Public Health Advisory. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm166996.htm. Accessed: June 16, 2009.
Schriever VA, Reither N, Gerber J, Iannilli E, Hummel T. Olfactory bulb volume in smokers. Exp Brain Res. 2013 Mar. 225(2):153-7. [Medline].
Negoias S, Croy I, Gerber J, Puschmann S, Petrowski K, Joraschky P. Reduced olfactory bulb volume and olfactory sensitivity in patients with acute major depression. Neuroscience. 2010 Aug 11. 169(1):415-21. [Medline].
Nguyen AD, Pelavin PE, Shenton ME, Chilakamarri P, McCarley RW, Nestor PG. Olfactory sulcal depth and olfactory bulb volume in patients with schizophrenia: an MRI study. Brain Imaging Behav. 2011 Dec. 5(4):252-61. [Medline].
Cecchini MP, Viviani D, Sandri M, Hahner A, Hummel T, Zancanaro C. Olfaction in People with Down Syndrome: A Comprehensive Assessment across Four Decades of Age. PLoS One. 2016. 11 (1):e0146486. [Medline].
Hüttenbrink KB, Hummel T, Berg D, Gasser T, Hähner A. Olfactory dysfunction: common in later life and early warning of neurodegenerative disease. Dtsch Arztebl Int. 2013 Jan. 110(1-2):1-7, e1. [Medline].
Barresi M, Ciurleo R, Giacoppo S, Foti Cuzzola V, Celi D, Bramanti P. Evaluation of olfactory dysfunction in neurodegenerative diseases. J Neurol Sci. 2012 Dec 15. 323(1-2):16-24. [Medline].
Wylie K, Nebauer M. "The food here is tasteless!" Food taste or tasteless food? Chemosensory loss and the politics of under-nutrition. Collegian. 2011. 18(1):27-35. [Medline].
Graham L, Murty G, Bowrey DJ. Taste, smell and appetite change after Roux-en-Y gastric bypass surgery. Obes Surg. 2014 Mar 8. [Medline].
Feng P, Huang L, Wang H. Taste bud homeostasis in health, disease, and aging. Chem Senses. 2014 Jan. 39(1):3-16. [Medline].
Gong W, Gao XC. [Clinical diagnosis and treatment of male Kallmann syndrome]. Zhonghua Nan Ke Xue. 2013 Dec. 19(12):1111-4. [Medline].
Damm M, Pikart LK, Reimann H, Burkert S, Göktas O, Haxel B. Olfactory training is helpful in postinfectious olfactory loss: A randomized, controlled, multicenter study. Laryngoscope. 2013 Aug 8. [Medline].
Pekala K, Chandra RK, Turner JH. Efficacy of olfactory training in patients with olfactory loss: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2015 Dec 1. [Medline].
Holbrook EH, Leopold DA. An updated review of clinical olfaction. Curr Opin Otolaryngol Head Neck Surg. 2006 Feb. 14(1):23-8. [Medline].
Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. Sniffin' sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses. 1997 Feb. 22(1):39-52. [Medline].
Jafek BW, Linschoten MR, Murrow BW. Anosmia after intranasal zinc gluconate use. Am J Rhinol. 2004 May-Jun. 18(3):137-41. [Medline].
Kern RC, Conley DB, Haines GK 3rd, Robinson AM. Pathology of the olfactory mucosa: implications for the treatment of olfactory dysfunction. Laryngoscope. 2004 Feb. 114(2):279-85. [Medline].
Nelson G, Chandrashekar J, Hoon MA, et al. An amino-acid taste receptor. Nature. 2002 Mar 14. 416(6877):199-202. [Medline].
Reed RR. After the holy grail: establishing a molecular basis for Mammalian olfaction. Cell. 2004 Jan 23. 116(2):329-36. [Medline].